Clinical Research Group 2 « Genetics of solid tumors »
Pr Florence PEDEUTOUR, PU-PH, Team Leader
The Laboratory of Solid Tumor Genetics was created in 2004 in the context of launch of the first the National Plan Against Cancer. The goal of this creation was to develop a translational activity in the field of genetics of solid tumors.
We are involved both in a clinical activity (affiliation: Nice University Hospital (CHU de Nice) and in a research program (affiliation: IRCAN). Our two main research interests are focused on genetics of soft tissue tumors and renal cell carcinomas, respectively. In addition, we closely interact with the French National Cancer Institute (INCa), the Cancéropôle Provence-Alpes-Côte d’Azur and the French Sarcoma Group (GSF-GETO). We also have a teaching and tutorial activity in oncology and genetics at the Faculty of Medicine of Nice as well as in national courses.
CLINICAL ACTIVITY IN SOMATIC CANCER GENETICS
The 28 French regional platforms were created in 2006 on the behalf of INCa in order to provide molecular tests for diagnosis and for predictive response to personalized targeted drugs (http://www.e-cancer.fr/soins/plates-formes-hospitalieres-de-genetique-moleculaire). Our clinical laboratory belongs to the Platform of Molecular Genetics of Cancers of the eastern part of Provence-Alpes-Côte d’Azur (PACA-est) region (six laboratories including ours; regional coordinator: F. Pedeutour).
Cytogenetic and molecular diagnosis
We provide a comprehensive test panel for diagnosis and evaluation of solid tumors, such as pediatric tumors, tumors of soft tissues and bones, brain tumors, skin tumors or renal tumors. We perform cytogenetic and molecular analyses as complementary tools of histopathological diagnosis, in collaboration with pathologists, surgeons and oncologists. We receive each year more than a thousand fresh, frozen or fixed-paraffin-embedded samples for chromosomal or molecular analyses. Depending on the indication and nature of the biological samples, we do cytogenetic analysis including preparation of karyotypes, metaphase and interphase based fluorescence in situ hybridization (FISH), comparative genomic hybridization based array (CGH array) as well as molecular analysis including mutation detection by RT-PCR, pyrosequencing, real time PCR or Sanger sequencing. The detection of somatic chromosomal alterations such as genomic amplification, translocations, fusion genes, deletions or DNA sequence anomalies such as nucleotide mutations is a powerful ancillary tool for diagnosis of solid tumors and therapeutic management. It helps the distinction between benign and malignant tumors and the recognition of a variety of malignant tumor types or subtypes. In particular, we are expert in the field of molecular diagnoses in sarcomas. Chromosomal analyses are also helpful for evaluation of prognosis (a typical example is the detection of MYCN amplification in neuroblastomas or genomic profiles in choroid melanomas).
Fig 1 :
Fig 2 :
Predictive molecular tests
A part of our clinical activity consists in detection of DNA mutations that are predictive of response or non-response to targeted therapies, such as tyrosine kinase inhibitors or monoclonal antibodies. The main current indications are mutations of KRAS, BRAF, EGFR, ALK, HER2, KIT and PDGFRA in colon cancers, lung cancers, melanomas and stromal gastro-intestinal tumors (GIST).
Fig 3 :
CLINICAL RESEARCH PROJECTS
Our research projects are closely related to our clinical activity. We aim: -1) to identify novel chromosomal and genetic anomalies in order to improve classification and diagnosis of solid tumors and -2) to explore the functional consequences of these novel anomalies.
Our current research projects are mainly dedicated to:
Molecular rearrangements and dysregulation of HMGA2 in adipose tissue tumors
Adipose tissue tumors are the most frequent human tumors. They are mainly represented by lipomas that are very common benign lesions. The malignant adipose tumors include three main subtypes, well-differentiated and dedifferentiated liposarcomas, myxoid and round cell liposarcomas and pleomorphic liposarcomas. The current challenges for improving the surgical and therapeutic management of adipose tumors are identification of novel diagnostic and prognostic markers as well as of therapeutic targets
Strikingly, it can be noted the high frequency of rearrangements of chromosome 12 long arm (12q). Indeed, chromosomal anomalies in lipomas mainly involve structural balanced and non-balanced alterations of chromosome 12 long arm in the region of HMGA2 (12q14.3) whereas amplification of the 12q14-15 region including MDM2 is the hallmark of well-differentiated/dedifferentiated liposarcomas and rearrangements of DDIT3 (12q13.3) are characteristic of myxoid liposarcomas. We have shown that HMGA2 is rearranged not only in lipomas but is also recurrently amplified in well-differentiated/dedifferentiated liposarcomas (Italiano et al., 2008 and 2009). We also recently reported the first observation of overexpression of HMGA2 in a unique case of lipomatosis (Saada et al., 2012). We therefore hypothesize that HMGA2 is a key gene in adipose lesions and tumors. We have shown that HMGA2 overexpression in lipomas is not always associated to chromosome 12q anomalies and is not significantly correlated to inhibition of let7 miRNA expression (Bianchini et al., 2011). Our aim is to understand the complex mechanisms of dysregulation of HMGA2 and how these alterations contribute to adipose tissue pathogenesis.
Genomic characterization of renal cell carcinomas
Renal cell carcinomas (RCC) account for approximately 10 500 novel cases/year in France and are responsible of the death of 4000 patients/year. The last World Health Organization (WHO) classification describes ten types of RCC, the most frequent of which are clear cell RCC followed by papillary RCC and chromophobe RCC. A precise and reliable histopathological typing of RCC is crucial since survival and response to treatment is variable from one type to another. Notably, since 2006 treatment of clear cell RCC has dramatically benefited from the use of targeted antiangiogenic molecules. However diagnosis of RCC is often difficult and approximately 15% of cases remain “unclassified”. Though some correlations between histology and genetics have been well established (for instance, deletion of VHL gene at 3p25 in clear cell RCC, trisomy 7 and 17 in papillary RCC or hypodiploidy in chromophobe RCC), programs of exploration of genomic and molecular profiles of RCC are necessary to improve our knowledge of these tumors. To note, a particular subtype, RCC with Xp11 translocation and rearrangement of TFE3 has been individualized thanks to chromosomal studies.
Since 2005 we have established a collaboration with the departments of Urology (PR Amiel) and the central laboratory of pathology (Pr Michiels) of Nice university hospital. We have karyotyped all RCC operated in the urology department (50/year). We have extended the chromosomal analyses by combining additional immunohistochemistry, FISH and array-CGH analysies. We have focused our research on two types of morphologically challenging RCC: RCC with Xp11 translocation and type 2-papillary RCC. Our aim is to use genomic tools to provide a better characterization of unclassified and rare subtypes of RCC.
« Genetics of solid tumors »
Our main research project is dedicated to the genomic and functional characterization of adipose tissue tumors (AT). AT are the most frequent human tumors, they include benign tumors such as lipomas and malignant tumors called liposarcomas. Deciphering the molecular events that trigger the oncogenic process of AT is crucial to thwart the morbid and sometimes lethal consequences of these malignancies. We have recently shown that the HMGA2 gene plays a crucial role in the pathogenesis of both benign and malignant AT. In lipomas, HMGA2 overexpression results from chromosomal translocations inducing rearrangements at the HMGA2 locus and fusion of this gene with various partners. In well differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS), HMGA2 overexpression results from an amplification process. A central theme in our explorations of benign and malignant AT focuses on the study of the role and the mechanisms of regulation of this gene.
Elucidation of HMGA2 dysregulation mechanisms- search for point mutations and polymorphisms (coding sequence and 3’UTR)- aberrant transcripts- silencing of expression in cells (WDLPS cell lines established in our laboratory) and in animal models- role of microRNAs
Identification of novel HMGA2 gene fusion partners and analysis of their potential role in tumorigenesis of AT
HMGA2 and telomeres
In collaboration with E. Gilson team we also plan to study the role of telomeric associations present in WDLPS in the AT tumorigenesis process as well as the potential role of HMGA2 - which modulates chromatine architecture - in telomere function.
CollaborationsInternational Liposarcoma Consortium : Ola Myklebost (Oslo) ; D. Thomas (Melbourne)Groupe Sarcomes Français - Groupe d’Etude des Tumeurs Osseuses (GSF-GETO)Team of C. Dani (Institut de Biologie Valrose, Nice)Team of P. Gual et A. Tran (INSERM U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice)
PEDEUTOUR Florence, PU-PH, Group LeaderTel : +33 (0)4 93 37 70 12, Mail :
Bianchini L, Birtwisle L, Saada E, Bazin A, Long E, Roussel J-F, Michiels J-F, Forest F, Dani C, Myklebost O, Birtwisle-Peyrottes I, Pedeutour F. Identification of PPAP2B as a novel recurrent translocation partner Gene of HMGA2 in lipomas. Genes, Chromosomes & Cancer, sous presse, 2013.
Doyen J, Carpentier X, Haudebourg J, Hoch B, Karmous-Benailly H, Ambrosetti D, Fabas T, Amiel J, Lambert JC, Pedeutour F. Renal cell carcinoma and a constitutional t(11;22)(q23;q11.2): case report and review of the potential link between the constitutional t(11;22) and cancer. Cancer Genet. 2012 Oct 29. [Epub ahead of print]
Burel-Vandenbos F, Ambrosetti D, Coutts M, Pedeutour F. EGFR mutation status in brain metastases of non-small cell lung carcinoma. J Neurooncol. 2012 Oct 20., [Epub ahead of print]
Bertucci F, Bouvier-Labit C, Finetti P, Adélaïde J, Metellus P, Mokhtari K, Decouvelaere AV, Miquel C, Jouvet A, Figarella-Branger D, Pedeutour F, Chaffanet M, Birnbaum D. Comprehensive genome characterization of solitary fibrous tumors using high-resolution array-based comparative genomic hybridization. Genes Chromosomes Cancer. 2012 Oct 17. [Epub ahead of print]
Calderaro J, Moroch J, Pierron G, Pedeutour F, Grison C, Maillé P, Soyeux P, de la Taille A, Couturier J, Vieillefond A, Rousselet MC, Delattre O, Allory Y. SMARCB1/INI1 inactivation in renal medullary carcinoma, Histopathology, 2012, Sept. 61 (3), 428-435.
Pedeutour F, Maire G, Pierron A, Thomas DM, Garsed DW, Bianchini L, Duranton-Tanneur V, Cortes-Maurel A, Italiano A, Squire JA, Coindre JM. A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions. Virchows Arch. 2012 Jul;461(1):67-78.
Saâda E, Bianchini L, Mouroux J, Dupré F, Butori C, Birtwisle-Peyrottes I, Padovani B, Yver M, Ferrari C, Pedeutour F. First description of inhibition of let-7 microRNA expression and HMGA2 overexpression in a case of deep-seated diffuse lipomatosis. Histopathology, 61.518-526, 2012
Pedeutour F, Deville A, Steyaert H, Ranchere-Vince D, Ambrosetti D, Sirvent N. Rearrangement of HMGA2 in a case of infantile lipoblastoma without PLAG1 alteration. Ped Blood Cancer, 58(5):798-800, 2012 (IF : 2,13)
Darini CY, Pisani DF, Hofman P, Pedeutour F, Sudaka I, Chomienne C, Dani C, Ladoux A. Self-renewal gene tracking to identify tumour-initiating cells associated with metastatic potential. Oncogene, 2011, 2012 (IF :7,216).
Wagner KD, Benchetrit M, Bianchini L, Michiels JF, Wagner N. Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) is highly expressed in liposarcoma and promotes migration and proliferation. J Pathol. 2011 Aug;224(4):575-88
Italiano A, Michalak S, Soulié P, Peyron AC, Pedeutour F. Trisomy 6p and ring chromosome 11 in a melanotic schwannoma suggest relation to malignant melanoma rather than conventional schwannoma. Acta Neuropathologica, 121(5):669-70, 2011 (IF : 5,31).
Bianchini L, Saâda E, Gjernes E, Marty M, Haudebourg J, Birtwisle-Peyrottes I, Keslair F, Chignon-Sicard B, Chamorey E, Pedeutour F. Let-7 microRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: analysis of 56 lipomas and liposarcomas with molecular cytogenetic data. Genes Chromosomes Cancer, 50: 442-455, 2011 (IF : 3,925)
Dujardin F, Binh MB, Bouvier C, Gomez-Brouchet A, Larousserie F, Muret AD, Louis-Brennetot C, Aurias A, Coindre JM, Guillou L, Pedeutour F, Duval H, Collin C, de Pinieux G. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol. 2011, sous presse, 24: 624-637, 2011 (IF : 4,678)
Leclerc-Mercier S, Pedeutour F, Fabas T, Glorion C, Brousse N, Fraitag S. A potentially misleading case of a Plexiform Fibro-Histiocytic Tumor in a child with molecular and cytogenetic analysis. Pediatric Dermatol, 28: 26-29, 2011. (IF :1,039)
Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, Gronchi A, Pilotti S, Casali PG. Dermatofibrosarcoma protuberans-derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib. Int J Cancer, 129 : 1761-1772, 2011 (IF : 4,734)
Saâda E, Peoc'h M, Decouvelaere AV, Collard O, Peyron AC, Pedeutour F. CCND1 and MET genomic amplification during malignant transformation of a giant cell tumor of bone. J Clin Oncol, 29:86-9, 2011. (IF : 17,157)
Watkin E, Devouassoux-Shisheboran M, Pedeutour F, Lagarde P, Salle M, Ranchère-Vince D, Baulieux J, Barnoud R. A First Reported Case of Dedifferentiated Liposarcoma of the Esophagus with Molecular Diagnosis. J Gastrointest Cancer. 42 :65-67, 2011
Sabatier R, Bouvier C, de Pinieux G, Sarran A, Brenot-Rossi I, Pedeutour F, Chetaille B, Viens P, Weiller PJ, Bertucci F. Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature. BMC Cancer. 10:645, 2010. (IF : 3,087)
Haudebourg J, Hoch B, Fabas T, Burel-Vandenbos F, Carpentier X, Amiel J, Cardot-Leccia N, Michiels JF, Pedeutour F.. A novel case of variant translocation t(X;1)(p11.2;p34) in a renal cell carcinoma with TFE3 rearrangement and favorable outcome in a 57-year-old patient. Cancer Genet Cytogenet, 200: 75-78, 2010. (IF : 1,482)
Haudebourg J, Hoch B, Fabas T, Cardot-Leccia N, Burel-Vandenbos F, Vieillefond A, Amiel J, Michiels JF, Pedeutour F. Strength of Molecular Cytogenetic Analyses for Adjusting the Diagnosis of Renal Cell Carcinomas with Both Clear Cells and Papillary Features: a Study of Three Cases. Virchows Arch, 457: 397-404, 2010. (IF : 2, 082)
Buche S, Delasalle EM, Coindre JM, Pedeutour F, Kolb F, Staumont-Salle D, Mortier L. Atypical presentation of giant cell fibroblastoma.Ann Dermatol Venereol. 2010 May;137(5):381-5. French.
Kérob D, Porcher R, Vérola O, Dalle S, Maubec E, Aubin F, D’Incan M, Bodokh I, Boulinguez S, Madelaine-Chambrin I, Mathieu- Boué A, Servant JM, de Kerviler E, Janin A, Calvo F, Pedeutour F, Lebbé C. Imatinib mesylate (IM) as a pre-operative therapy in dermatofibrosarcoma : results of a multicentric phase II study on 25 patients. Clin Cancer Res, 16:3288-3295, 2010. (IF : 6,488)
Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, Gugenheim J, Becouarn Y, Brunet R, Fonck M, François E, Saint-Paul MC, Pedeutour F. KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications. Ann Surg Oncol, 17: 1429-1434, 2010. (IF: 3,898)
Giacchero D, Maire G, Nuin P.A.S, Berthier F, Ebran N, Carlotti A, Celerier P, Coindre J. M, Esteve E, Fraitag S, Guillot B, Ranchere-Vince D, Saiag P, Terrier P, Lacour J.P, Pedeutour F. No correlation between the molecular subtype of COL1A1-PDGFB fusion gene and the clinico-histopathological features of dermatofibrosarcoma protuberans. J Invest Dermatol, 130:904-907, 2010. (IF : 5.251)
Pierron A, Fernandez C, Saada E, Keslair F, Hery G, Zattara H, Pedeutour F. HMGA2-NFIB fusion in a pediatric intramuscular lipoma: a novel case of NFIB alteration in a large deep-seated adipocytic tumor. Cancer Genet Cytogenet, 2009, 195 : 66-70. (IF : 1,482)
Sirvent N, Trassard M, Ebran N, Attias R, Pedeutour F. Fusion of EWS with the DUX4/Fascioscapulohumeral muscular dystrophy region resulting from a (4;22)(q35;q12) in a case of embryonal rhabdomyosarcoma. Cancer Genet Cytogenet, 2009, 195 :12-18. (IF : 1,482)
Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere-Vince D, Dumollard JM, Haudebourg J, Leroux A, Mainguené C, Terrier P, Chibon F, Coindre JM, Pedeutour F. Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated Liposarcomas. Clin Cancer Res, 5: 5696-703, 2009. (IF : 6,488)
Coindre JM, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch. 2010 Feb;456(2):167-79. Epub 2009 Aug 18. Review
Italiano A, Cortot AB, Ilie M, Martel-Planche G, Fabas T, Pop D, Mouroux J, Hofman V, Hofman P, Pedeutour F. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy Int J Cancer, 125:2479-82, 2009. (IF : 4,734)
Pires de Camargo V, van de Rijn M, Maestro R, de Alava E, Madoz-Gúrpide J, Pilotti S, von Mehren M, Pedeutour F, Maki RG, Rutkowski P, Thomas DM. Other targetable sarcomas. Semin Oncol. 2009 Aug;36(4):358-71
Hélias-Rodzewicz Z, Pedeutour F, Coindre JM, Terrier P, Aurias A. Selective Elimination of Amplified CDK4 Sequences Correlates with Spontaneous Adipocytic Differentiation in Liposarcoma. Genes Chromosomes Cancer, 48:943-952, 2009. (IF : 3,925)
Bidault F, Vanel D, Terrier P, Jalaguier A, Bonvalot S, Pedeutour F, Couturier JM, Dromain C. Liposarcoma or lipoma: Does genetics change classic imaging criteria? Eur J Radiol. 72 :22-26, 2009
Ilie M, Hofman V, Pedeutour F, Attias R, Santini J, Hofman P. Oncocytic lipoadenoma of the parotid gland: Immunohistochemical and cytogenetic analysis. Pathol Res Pract. 2010 Jan 15;206(1):66-72. Epub 2009 Apr 5.
Raoux D, Péoc'h M, Pedeutour F, Vaunois B, Decouvelaere AV, Folpe AL. Primary epithelioid sarcoma of bone: report of a unique case, with immunohistochemical and fluorescent in situ hybridization confirmation of INI1 deletion. Am J Surg Pathol. 2009 Jun;33(6):954-8.
Marque M, Bessis D, Pedeutour F, Viseux V, Guillot B, Fraitag-Spinner S. Medallion-like dermal dendrocyte hamartoma: the main diagnostic pitfall is congenital atrophic dermatofibrosarcoma. Br J Dermatol. 2009 Jan;160(1):
Italiano A, Maire G, Sirvent N, Nuin P.A.S, Keslair F, Foa C, Louis C, Aurias A, Pedeutour F. Variability of Origin for the Neocentromeric Sequences in Analphoid Supernumerary Marker Chromosomes of Well-Differentiated Liposarcomas. Cancer Letters, 273:323-30, 2009. (IF : 3,504)
Italiano A, Ebran N, Attias R, Chevallier A, Monticelli I, Mainguené C, Benchimol D, Pedeutour F. NFIB Rearrangement in Superficial, Retroperitoneal and Colonic Lipomas with Chromosome 9p22 Aberrations. Genes Chromosomes Cancer, 47:971-977, 2008. (IF : 3,925)
Cardot-Leccia N, Italiano A, Haudebourg J, Attias R, Amato D, Pedeutour F, Perrin C. Cutaneous myxolipoma with apocrine glandular differentiation: description of a new clinico-pathological variant with chromosome 6p21 rearrangement, Histopathology, 53:361-363, 2008. (IF : 4,131)
Italiano A, Chambonniere M-L, Attias R, Chibon F, Coindre J-M, Pedeutour F. Monosomy 7 and absence of 12q amplification in two cases of spindle cell liposarcomas. Cancer Genet Cytogenet, 184:99-10, 2008. (IF : 1,482)
Rouzier C, Soler C, Hofman P, Brennetot C, Bieth E, Pedeutour F. Ovarian dysgerminoma and Apert syndrom. Pediatric Blood Cancer, 50:696-8, 2008. (IF : 2,394)
Rouzier C, Haudebourg J, Carpentier X, Valério L, Amiel J, Michiels JF, Pedeutour F. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin embedded samples with clinical data. Cancer Genet Cytogenet, 183: 21-27, 2008. (IF : 1,482)
Kerob D, Pedeutour F, Leboeuf C, Verola O, de Kerviler E, Servant JM, Sarandi F, Bousquet G, Madelaine-Chambrin I, Pruvost C, Calvo F, Janin A, Lebbe C. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol, 26:1757-9, 2008. (IF : 17,157)
Surace C, Pedeutour F, Trombetta D, Burel-Vandenbos F, Rocchi M, Storlazzi CT. MYCN is uncommonly amplified in the form of episomes in a case of medulloblastoma. Virchows Arch, 452:491-7, 2008. (IF : 2, 082)
Bianchini L, Maire G, Guillot B, Joujoux JM, Follana P, Simon MP, Coindre JM, Pedeutour F. Complex t(5;8) involving the CSPG2 and PTK2B genes in a Case of Dermatofibrosarcoma Protuberans without the COL1A1-PDGFB Fusion. Virchows Arch, 452:689-96, 2008. (IF : 2, 082)
Italiano A, Bianchini L, Keslair F, Bonnafous S, Cardot-Leccia N, Coindre JM, Dumollard JM, Hofman P, Leroux A, Mainguené C, Peyrottes I, Ranchere-Vince D, Terrier P, Tran A, Gual P, Pedeutour F. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer. 2008 May 15;122(10):2233-41.
Benchetrit M, Hofman V, Long E, Odin G, Basc E, Pasquier B, Pedeutour F, Hofman P. Primary Clear Cell Meningioma of the Orbit Mimicking a Metastatic Carcinoma. Usefulness of Immunohistochemistry and Cytogenetic Analysis. Virchows Arch, 2008, 452:209-13. (IF : 2, 082)
Italiano A, Follana P, Caroli FX, Badetti JL, Benchimol D, Garnier G, Gugenheim J, Haudebourg J, Keslaier F, Lesbats G, Lledo G, Roussel JF, Pedeutour F, François E. Cetuximab shows activity in colorectal patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Annals of Surgical Oncolgy, 15:649-54, 2008. (IF : 3,898)
Benchetrit M, Hofman V, Venissac N, Italiano A, Aurias A, Brennetot C, Pedeutour F, Hofman P. Dedifferentiated liposarcoma of the pleura mimicking a malignant solitary fibrous tumor and associated with dedifferentiated liposarcoma of the mediastinum. Usefulness of cytogenetic and molecular genetics analyses. Cancer Genet Cytogenetics, 2007, 179 : 150-155. (IF : 1,482)
Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, Guillou L, Ranchere-Vince D, Terrier P, Pedeutour F. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol, 31:1476-1489, 2007. (IF : 4,181)
Guillou L, Benhattar J, Gengler C, Gallagher G, Ranchere-Vince D, Collin F, Terrier P, Leroux A, Marquès B, de Saint-Aubain-Sommerhausen N, Keslair F, Pedeutour F, Coindre J-M. Translocation-positive low grade fibromyxoid sarcoma : clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma. A study from the french sarcoma group. Am J Surg Pathol, 31:1387-1402, 2007. (IF : 4,181)
Jouary T, Beltran C, Coindre JM, Plagnol P, Taieb A, Ebran N, Pedeutour F, Delaunay M.Dermatofibrosarcoma protuberans occurring in two brothers : role of environmental or genetic factors ? J Am Acad Dermatol, 57:S58-60, 2007. (IF : 4,081)
Italiano A, Cardot N, Dupré F, Monticelli I, Keslair F, Piche M, Mainguené C, Coindre JM, Pedeutour F. Gains and Complex Rearrangements of the 12q13-15 Chromosomal Region in Ordinary Lipomas: the “Missing Link” Between Lipomas and Liposarcomas? Int J Cancer, 121: 308-315, 2007. (IF : 4,555)
Müller CR, Paulsen E, Noordhuis P, Pedeutour F, Sæter G, Vassilev LT, Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer, 121: 199-205, 2007. (IF : 4,555)
Bianchini L, Maire G, Pedeutour F; Groupe Francophone de Cytogénétique Oncologique. From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors.Bull Cancer. 2007 Feb;94(2):179-89.
Maire G, Fraitag S, Galmiche L, Keslair F, Ebran N, Terrier-Lacombe MJ, de Prost Y, Pedeutour F. A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol. 2007 Feb;143(2):203-10.
Cardot-Leccia N, Italiano A, Monteil MC, Basc E, Perrin C, Pedeutour F. Naevus lipomatosus superficialis: a case report with a deletion 2p24. Br J Dermatol, 156:380-381, 2007. (IF : 3,489)
Craver R, Dewenter T, Ebran N, Pedeutour F. COL1A1-PDGFB fusion in a pediatric Bednar tumor with 2 copies of der(17;22), Cancer Genet Cytogenet,168: 155-157, 2006. (IF : 1,482)
Harik LR, Merino C, Coindre JM, Amin MB, Pedeutour F, Weiss SW. Pseudosarcomatous Myofibroblastic Proliferations of the Bladder. A Clinicopathologic Study of 42 Cases. Am J Surg Pathol, 30 :787-794, 2006. (IF : 4,144)
Hieronimus S, Bec-Roche M, Pedeutour F, Lambert J-C, Wagner-Mahler K, Mas J-C, Sadoul J-L, Fénichel P. The spectrum of parathyroid gland dysfunction associated with the microdeletion 22q11. Eur J Endocrinology, 155 :47-52, 2006. (IF : 3,145)
Butori C, Hofman V, Attias R, Mouroux J, Pedeutour F, Hofman P. Diagnosis of Primary Esophageal Synovial Sarcoma by Demonstration of t(X;18) Translocation. A Case Report. Virchows Arch, 449:262-7, 2006. (IF : 2, 082)
Italiano A, Attias R, Aurias A, Pérot G, Burel-Vandenbos F, Otto J, Venissac N, Pedeutour F. Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 Neocentromere and 9p23-24 amplification including JAK2 and JMJD2C. Cancer Genet Cytogenet, 167:122-130, 2006. (IF : 1,482)
Kostrzewa E, Beylot-Barry M, Vergier B, Pedeutour F, Beylot C. Childhood-onset multifocal atrophic dermatofibrosarcoma. Ann Dermatol Venereol. 2006 Apr;133(4):359-61.
Italiano A, Burel Vandenbos F, OttoJ, Mouroux J, Fontaine D, Marcy P-Y, Cardot N, Thyss A Pedeutour F. Comparison of Epidermal Growth Factor Receptor Gene and Protein in Primary Non-Small-Cell-Lung Cancer and Metastatic Sites: Implications for Treatment with EGFR-Inhibitors. Annals of Oncology, 17:981-5, 2006. (IF : 5,179).